| Date Filed | Type | Description |
| 02/12/2021 |
SC 13G/A
| Allianz Global Investors U.S. Holdings LLC reports a 0% stake in Assertio Therapeutics, Inc. |
| 06/18/2020 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 05/22/2020 |
8-K
| Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T... |
| 05/19/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/18/2020 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/11/2020 |
4
| DAWES KAREN A (Director) has filed a Form 4 on Assertio Therapeutics, Inc|
Txns:
| Sold 15,834 shares
@ $0.7914, valued at
$12.5k
|
|
| 05/11/2020 |
10-Q
| Quarterly Report for the period ended March 31, 2020 |
| 05/11/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 04/24/2020 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 04/20/2020 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/08/2020 |
SC TO-I/A
| Form SC TO-I/A - Tender offer statement by Issuer: [Amend] |
| 04/08/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 04/03/2020 |
4/A
| Bukofzer Stan (SVP, Chf Scitfc & Tech Officer) has filed a Form 4 on Assertio Therapeutics, Inc|
Txns:
| Paid exercise price by delivering 7,433 shares
@ $0.6467, valued at
$4.8k
Exercised 25,370 restricted stock units
@ $0 |
|
| 04/03/2020 |
4
| Bukofzer Stan (SVP, Chf Scitfc & Tech Officer) has filed a Form 4 on Assertio Therapeutics, Inc|
Txns:
| Paid exercise price by delivering 7,433 shares
@ $0
Exercised 25,370 restricted stock units
@ $0 |
|
| 03/31/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/26/2020 |
SC 13D
| DEPOMED INC reports a 51% stake in Zyla Life Sciences |
| 03/25/2020 |
SC TO-I/A
| Form SC TO-I/A - Tender offer statement by Issuer: [Amend] |
| 03/17/2020 |
8-K
| Asset disposition|
Docs:
|
"Agreement and Plan of Merger by and among Assertio Therapeutics, Inc., Alligator Zebra Holdings, Inc., Alligator Merger Sub, Inc., Zebra Merger Sub, Inc. and Zyla Life Sciences",
"Form of Voting and Support Agreement by and among Alligator Zebra Holdings, Inc. and certain Zyla stockholders",
"Form of Voting and Support Agreement by and among Alligator Zebra Holdings, Inc. and certain Zyla stockholders",
"Transition Agreement by and among Assertio Therapeutics, Inc. and Arthur Higgins",
"Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive Chairman and Todd Smith to be Named President and CEO of Combined Company",
"Employee FAQs",
"Investor Presentation" |
|
| 03/17/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/11/2020 |
SC TO-I
| Form SC TO-I - Tender offer statement by Issuer: |
| 03/11/2020 |
8-K
| Quarterly results |
| 03/10/2020 |
10-K
| Annual Report for the period ended December 31, 2019 |
| 03/09/2020 |
8-K
| Quarterly results |
| 02/20/2020 |
8-K
| Quarterly results |
| 02/19/2020 |
4
| Mason Heather L (Director) has filed a Form 4 on Assertio Therapeutics, Inc|
Txns:
| Exercised 14,394 restricted stock units
@ $0 |
|
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2020 |
8-K
| Quarterly results |
| 02/13/2020 |
SC 13G
| Allianz Global Investors U.S. Holdings LLC reports a 7.3% stake in Assertio Therapeutics, Inc. |
| 02/12/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/12/2020 |
4
| HIGGINS ARTHUR J (Director, President and CEO) has filed a Form 4 on Assertio Therapeutics, Inc|
Txns:
| Paid exercise price by delivering 31,008 shares
@ $1.35, valued at
$41.9k
Exercised 97,412 restricted stock units
@ $0 |
|
| 02/12/2020 |
4
| Bukofzer Stan (SVP, Chf Scitfc & Tech Officer) has filed a Form 4 on Assertio Therapeutics, Inc|
Txns:
| Paid exercise price by delivering 9,545 shares
@ $1.35, valued at
$12.9k
Exercised 27,588 restricted stock units
@ $0 |
|
|